Seminar Title: “Mechanistic Insights for Immunotherapy Driven Phagocytosis of Amyloid Plaque, Clinical Translation, and Next Generation Anti-Amyloid Therapies.”
Speaker: Ronald B. DeMattos, PhD. Retired Senior Vice President and Chief Scientific Officer for Neurobiologics at Eli Lilly and Company.
Dr. DeMattos received his doctorate in molecular and cellular biochemistry (SUNY – Stony Brook, 1998) and performed a post‑doctoral fellowship at Washington University School of Medicine (Holtzman Lab). Dr. DeMattos joined Eli Lilly in 2002 and has since held multiple scientific positions within Neuroscience Discovery over the last 20+ years. He discovered and developed numerous compounds that progressed to clinical studies in Alzheimer’s disease patients, including Solanezumab, Donanemab (FDA‑approved Kisunla), and Remturnetug (Phase‑3 ongoing). He currently leads multiple discovery projects while managing the Indianapolis Neurodegeneration Discovery group, whose mission is to develop novel first‑in‑class therapies for neurodegeneration and Alzheimer’s disease.
Hosted in Daniel Hale Williams Auditorium and via Zoom.
Registration is required to attend via Zoom. Zoom link will be provided via email upon completing the registration form.
Cost: FREE
Darby Morhardt
(312) 908-9432
Email